In this week's Pharma Pulse, nine more drugmakers join the MFN program, GoodRx adds a family plan, IPC formalizes its USave partnership, and CSafe expands its thermal cover offerings.
News|Podcasts|March 13, 2026
Pharma Pulse: SteinCares Partners to Expand Biosimilar Access in Latin America and Eli Lilly Issues Warning Over Compounded Tirzepatide Safety
Author(s)Stephen Appezzato
In today’s Pharma Pulse, Eli Lilly issues a safety warning and SteinCares enters a licensing agreement with Shilpa Biologicals to expand biosimilar access in Latin America.
Advertisement
Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast in which we bring you the latest insights shaping patient access and healthcare innovation. I’m your host, and let's get into today's headlines.
- SteinCares and Shilpa Biologicals have entered a
licensing agreement to commercialize biosimilars in Latin America. Under the deal, SteinCares will manage regional registration and distribution, while Shilpa handles product development and long-term manufacturing to increase access to cost-effective biologics. - In other news, Eli Lilly has released an open letter
warning of potential safety risks associated with compounded tirzepatide mixed with Vitamin B12. Testing revealed significant impurity formation due to chemical incompatibility, which the company says introduces unknown toxicological risks. Consequently, Lilly has requested the FDA initiate a nationwide recall of products containing these untested additives.
That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access, visit
Thanks for listening—until next time, stay well and stay informed.
You can catch Pharma Pulse directly on
Advertisement
Related to this article
In this week's Pharma Pulse, Vicapsys merges with Stateline, Veritiv targets GLP-1 shipping, Section 232 tariffs widen and HRSA's 340B rebate pilot deadline arrives.
Go behind the scenes of LogiPharma USA 2026 with program director Charleen Ring and McKesson's Chris Van Norman in this Pharma Pulse special.
In this week's Pharma Pulse, DHL breaks ground on a new cold chain hub at Singapore's Changi Airport, a new report finds pharma's commercial model in the middle of a fundamental reset, and the FDA grants accelerated approval to sevabertinib.
Ed Schoonveld examines the uncertainty surrounding President Trump's MFN drug pricing agreements, stalled GENEROUS, GLOBE and GUARD proposals, and their ripple effects on ex-US drug launches.
With HRSA's approval window now closed, attention turns to whether health system pharmacies can reconcile rebates at scale before the pilot's Jan. 1 start.
Episode 3 of Supply Chain Signal examines the Aug. 31 MFN agreements with nine mid-size manufacturers, the GENEROUS Medicaid model and whether pricing, trade and manufacturing policy now add up to a new pharma operating model.
Valerie Bandy of Tecsys on where 340B rebate mechanics threaten pharmacy purchasing, and how stakeholders can prevent disruption.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
FAQ: What Comes Next for the 340B Rebate Pilot
2
How Early Development Decisions Shape Commercial Readiness for Biologics
3
Pharma Pulse: Vicapsys-Stateline Merger and Veritiv's TempSafe RxShield
4
Why Early, Big-Picture Planning Is Key to Execution Across the CGT Lifecycle
5